Medtronic has reported total revenue of $36.4bn in fiscal year 2026 (FY26), a figure the company said reflects the highest annual growth achieved in 10 years.
With FY26 revenue indicative of a year-over-year (YoY) rise of 8.4%, Med-ABtronic expects FY27 growth to fall in 6.75% to 7.25% range on an organic basis, with earnings mooted to fall in the $5.90 to $6.00 per share range
The medtech giant’s cardiovascular portfolio, which includes the PulseSelect pulsed-field ablation (PFA) system, was its strongest performing business segment in FY26, with revenue around $13.98bn, denoting a 12% uptick YoY. Meanwhile, Medtronic’s Neuroscience and MedSurg business lines came in at around $10.3bn and $8.8bn, corresponding to YoY uplifts of 4.5% and 4.9%, respectively. Alongside its FY26 financials, Medtronic also reported its Q4 FY26 results, achieving total revenue of $9.81bn.
The figure beat analysts’ estimates of $9.63bn, according to data compiled by the London Stock Exchange Group (LSEG) and seen by Reuters. The total also bested Medtronic’s Q3 FY26 performance by around $800m. In Q4, Medtronic’s cardiovascular business grew 13.8% YoY to around $3.8bn, while Neuroscience and MedSurg saw YoY growth of 5% and 8% to around $2.75bn and $2.39bn, respectively.